Skip to content

Press Releases

Every day, more lives are transformed all over the world – one healthy habit at a time. Read the latest about how Medifast and the OPTAVIA® movement is impacting people’s lives.

New `Maintain by Medifast™' Low Carbohydrate Program Successfully Launched on Regional TV Retailer and Scheduled for National Launch in July
Medifast Executive Appointed to Maryland State Board of Directors for the American Diabetes Association

Medifast, Inc. announced today that the new "Maintain by Medifast" low-carb program was successfully launched in selected regions on a prominent TV retailer this week. As a result of its success, this new Medifast program will be launched on a national cable TV retailer in July. "Maintain by Medifast" is a low-calorie, soy-based, low glycemic formula patented by Medifast that is incorporated into a low carbohydrate diet that has provided significant weight loss results and overall health improvements in clinical studies. "Maintain by Medifast" offers consumers a special 28-day program that will provide immediate results on the journey to long-term health improvement.

Medifast's Chairman of the board, Bradley T. MacDonald, also announced that its Corporate Executive Vice President, Retired Maj. Gen. Leo V. Williams, III, USMCR, was elected to the Maryland State Board of Directors of the American Diabetes Association (ADA) and is representing the state at the National ADA Conference currently taking place in Orlando.

"Leo has an exemplary record of public service, serving his country for 33 years in the Marine Corps and he continues to serve by providing leadership to fight the national epidemic of diabetes within the ADA," states MacDonald. "The opportunity for Medifast to provide nutritional therapy to reduce diabetes, especially in the African-American and Hispanic communities of our nation, is enormous."

Medifast Plus for Diabetics was developed to reduce the incidence of Type II diabetes in the U.S. Recent clinical studies at the Johns Hopkins Bloomberg School of Public Health have helped put Medifast in a leadership position for providing nutritional intervention products to combat this dreadful disease state.

Preliminary Results from clinical studies at the Johns Hopkins Bloomberg School of Public Health included:

   -- After 34 weeks the study showed that those on the Medifast Diet for
      Diabetics lost twice as much weight compared to those following basic
      nutrition recommendations from the American Diabetes Association

   -- Those on the Medifast Diet for Diabetics program lost an average of
      16 pounds compared to the ADA diet group that lost an average of
      8 pounds.

   -- Two-Thirds of those on the Medifast program lost at least 5% of their
      weight, which is a standard measure of the Food and Drug
      Administration's (FDA) threshold to indicate clinically significant
      weight loss, versus one-quarter of those on the ADA diet.

   -- The researchers randomized two groups of Type II diabetics.  One group
      was given the Medifast Plus for Diabetics defined-formula meal
      replacement diet of soups, oatmeal, bars and a variety of shakes.  The
      other group was asked to follow a diet based on the ADA nutrition
      guidelines, shop for their own food and manage their own portions, but
      had the same guidance from the doctors, counselors and dietitians in
      the study as the Medifast group.

   -- The study found those randomized to the Medifast program had an
      average 7.5% decrease in body fat, a clinically significant amount.

This release contains forward-looking statements, which may involve known, and unknown risks, uncertainties and other factors that may cause Medifast's actual results and performance in future periods to be materially different from any future results or performance suggested by these statements. Medifast cautions investors not to place undue reliance on forward-looking statements, which speak only to management's expectation on this date.

SOURCE: Medifast, Inc.

CONTACT: Jeremy Hunt, Investor Relations Specialist, +1-410-504-8196, or
Casey Seward, Public Relations Manager, +1-410-504-8154, both of Medifast; or
Ken Sgro, CEOcast, Inc. for Medifast, +1-212-732-4300